NCT06930651 2026-05-06A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid MalignanciesM.D. Anderson Cancer CenterPhase 1/2 Recruiting42 enrolled